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Abstract
Purpose: To investigate whether whole brain irradiation might be replaced by focalized irradiation after resection of a single brain
metastasis in patients where extracranial tumor control is deemed to be obtained.
Patients and methods: Twelve patients were introduced in a phase I/II prospective study of conformal postoperative external irradiation
after resection of a solitary brain metastasis. The radiation treatment consisted of 50.4 Gy (1.8 Gy per fraction, five fractions per week). The
planning target volume consisted of the tumor bed and a 2 cm safety margin. All treatments were optimized with head immobilization,
dedicated tomodensitometry and computer assisted three-dimensional treatment planning.
Results: The median survival was 7.2 months (range 2.4–50.4 months). Eleven of the 12 patients died. Eight of the 12 patients presented
intracranial recurrence and seven died as a consequence of intracranial tumor progression.
Conclusions: Focalized external irradiation cannot serve as a reasonable alternative to whole brain radiotherapy (WBRT) even for
patients with apparently one single resected brain metastasis. The dogma of ‘one metastasis = multiple metastases’ seems to be
confirmed. Ó 1998 Elsevier Science Ireland Ltd.
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1. Introduction
The optimal treatment for a single brain metastasis
remains to be established [1,9]. Local control and survival
were reported to be higher if surgery was combined with
radiotherapy as compared to radiotherapy alone in two ran-
domized studies [2,3] and retrospectives series [5]. Survival
after resection has been questioned and irradiation for a
single brain metastasis is potentially of long duration.
Therefore, the dogma of whole brain irradiation after resec-
tion should be questioned, especially when considering the
potential risk of late toxicity. To decrease the potential det-
rimental effect of whole brain irradiation (WBRT) [4], foca-
lized external beam irradiation could be used as an
alternative to WBRT, provided the pattern of disease recur-
rence is mainly extracerebral. There are currently no valid
data available on the feasibility and efficacy of focalized
external beam irradiation of the tumor bed after resection
of a single brain metastasis. Therefore, we initiated a phase
I/II trial to define the site of first recurrence after focalized
radiotherapy treatment and to question the widely accepted
dogma of WBRT.
2. Patients and methods
Between April 1991 and December 1993, 12 patients
were included in a prospective phase I/II study aimed at
assessing the feasibility of focalized external irradiation
after surgical resection for a single brain metastasis. Metas-
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tases from small cell lung cancer and malignant lymphoma
were not eligible. In order to exclude other secondary
lesions within the brain, all patients were submitted to
both brain tomodensitometry (CT) and nuclear magnetic
resonance (NMR). For the present phase I/II study, eligibil-
ity criteria included that the primary tumor had to be con-
trolled and that no other extracranial metastases were
discovered.
The postoperative irradiation was delivered after three-
dimensional computer-assisted treatment planning (TPS).
The CT slices required for spatial reconstruction of the tar-
get were obtained in a head immobilization mask (ORFIT
Raycast, Uehlinger Pfiffner AG, Switzerland). The transfer
of CT images to the TPS was done by an Ethernet link. The
region of interest was irradiated conformally with multiple
static beams (two to three beams) and individualized cerro-
bend blocks. A total dose of 50.4 Gy was applied on the
ICRU-50 point (intersection of the beams). Patients
received daily fractions of 1.8 Gy, five times per week.
These treatments were performed with a linear accelerator
producing at least 6 MV photons. The median time between
surgery and initiation of radiotherapy was 26 days (range 8–
72 days). Only five patients were kept on steroids during
irradiation. No anticancer chemotherapy was applied except
for one patient with testicular embryonal carcinoma.
After completion of the external radiation therapy, the
patients were followed on a regular basis until death. Radi-
ological follow-up with CT and/or NMR was done on a
regular basis or if disease progression was suspected
based on clinical symptoms.
3. Results
The patient characteristics are listed in Table 1. Strik-
ingly, a large majority had an adenocarcinoma from various
origins, which is a common feature in the case of a single
brain metastasis. As illustrated in Table 2, we observed an
improvement in terms of performance status after treatment
by surgery and radiotherapy for these patients bearing single
brain metastases. This clearly illustrates the potential advan-
tage of treating those patients as far as quality of life is
concerned. The median survival was 7.2 months (range
2.4–50.4 months). Eleven of the 12 patients died from
their disease. Seven of those died because the tumor
recurred in the brain. Four patients died from extracranial
metastatic disease. One of the latter also presented with
intracranial failure. Only one patient is currently alive with-
out evidence of disease 4 years after treatment. Overall,
eight of the 12 patients developed intracranial failure. The
distribution of brain failures has been listed according to
their locations in Table 3. Interestingly, there were no fail-
ures reported inside the treated area, i.e. in-field, as the sole
site of recurrence. However, failures outside the treated
volume are the main reason for intracranial failure. Most
of those brain failures were multiple; four patients devel-
oped multiple foci and two patients presented carcinoma-
tous meningitis. Only two out of eight patients had only one
site of brain failure. There is only one patient alive in this
series; he presented with a brain metastasis from a clear cell
adenocarcinoma of the kidney. The patient with a primary
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Renal and lung 1 (renal origin)
Ovary and breast 1 (ovarian origin)
Colon and prostate 1 (colon origin)







Interval from primary diagnosis














1 1 2 5
2 2 6 5
3 8 3 1
4 1 1 1
WHO, World Health Organization.
Table 3
Distribution of intracranial recurrences
No
failure
IF OF M IF + OF M + IF + OF Total
4 0 3 2 2 1 8
IF, in-field; OF, out-field; M, meningeal.
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embryonal carcinoma of the testicle, which progressed dur-
ing external irradiation, received chemotherapy but died 1
year after radiation treatment.
This phase I/II study was stopped after only 12 patients
due to the unacceptably high rate of central nervous system
failures.
4. Discussion
Despite the reported series [2,3,5–7] of an increased sur-
vival after treatment of solitary brain metastases, especially
in patients submitted to surgery, our results were disappoint-
ing. We observed a high intracranial failure rate (eight out of
12) and a short median survival (7.5 months) after resection
and focalized external radiation therapy. Noordijk et al. [3]
reported a median survival of 10 months in 32 patients after
resection followed by accelerated whole brain radiation
therapy at a dose of 40 Gy (b.i.d. in 2 weeks). Patchell et
al. [2] described a median survival of 40 weeks in their
series of 25 patients treated with surgery and hypofractio-
nated WBRT (36 Gy in 12 fractions).
One could argue against the use of high-dose multifrac-
tionated treatment in this population of patients character-
ized by a short median survival [8]. However, this treatment
schedule was chosen because of concern regarding late toxi-
city in patients for whom potential long survival after resec-
tion of a solitary brain metastasis has been described. In the
present series, a high dose (50.4 Gy) focalized irradiation
yielded a high in-field local control. However, the out-field
intracranial progression rate and subsequent death rate is
unacceptable. Therefore, the dogma which states that the
concept of a ‘solitary’ brain metastasis is merely an illustra-
tion of the lack of resolution of current radiological imaging
techniques in detecting the presence of micrometastatic dis-
ease seems to be illustrated by our results on a small number
of patients.
We conclude that focalized external radiotherapy after
resection of a solitary brain metastasis is not a safe proce-
dure as far as intracranial control is concerned. Should we
question the role of WBRT after stereotactic radiation ther-
apy of a ‘solitary’ brain metastasis, or rather the impact of a
high-dose stereotactic boost added to moderate doses of
WBRT in a randomized trial?
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